Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:CSII
- CUSIP: 14161910
- Web: www.csi360.com
Capitalization:- Market Cap: $1.07 billion
- Outstanding Shares: 32,712,000
Average Prices:- 50 Day Moving Avg: $31.70
- 200 Day Moving Avg: $29.04
- 52 Week Range: $18.82 - $33.11
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 545.33
- P/E Growth: -16.85
Sales & Book Value:- Annual Revenue: $199.17 million
- Price / Sales: 5.37
- Book Value: $3.47 per share
- Price / Book: 9.43
Profitability:- EBIDTA: ($1,900,000.00)
- Net Margins: -3.72%
- Return on Equity: -4.36%
- Return on Assets: -2.99%
Debt:- Debt-to-Equity Ratio: 0.18%
- Current Ratio: 3.93%
- Quick Ratio: 3.50%
Misc:- Average Volume: 327,765 shs.
- Beta: 2.6
- Short Ratio: 3.71
Frequently Asked Questions for Cardiovascular Systems (NASDAQ:CSII)
What is Cardiovascular Systems' stock symbol?
Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."
How were Cardiovascular Systems' earnings last quarter?
Cardiovascular Systems, Inc. (NASDAQ:CSII) announced its quarterly earnings results on Wednesday, May, 3rd. The company reported ($0.05) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.05). The company had revenue of $52.10 million for the quarter, compared to analysts' expectations of $51.13 million. Cardiovascular Systems had a negative net margin of 3.72% and a negative return on equity of 4.36%. The business's quarterly revenue was up 17.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.31) earnings per share. View Cardiovascular Systems' Earnings History.
When will Cardiovascular Systems make its next earnings announcement?
What guidance has Cardiovascular Systems issued on next quarter's earnings?
Cardiovascular Systems updated its fourth quarter earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of ($0.06)-($0.04) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.03). The company issued revenue guidance of $51.5-$52.5 million, compared to the consensus revenue estimate of $53.79 million.
Where is Cardiovascular Systems' stock going? Where will Cardiovascular Systems' stock price be in 2017?
6 analysts have issued 12 month target prices for Cardiovascular Systems' shares. Their forecasts range from $30.00 to $40.00. On average, they expect Cardiovascular Systems' share price to reach $34.40 in the next twelve months. View Analyst Ratings for Cardiovascular Systems.
What are analysts saying about Cardiovascular Systems stock?
Here are some recent quotes from research analysts about Cardiovascular Systems stock:
- 1. Needham & Company LLC analysts commented, "We are reiterating our Buy rating on CSII, raising our FY18 and FY19 estimates, and raising our price target to $37 from $32. Over the next few quarters, we expect revenue growth to slow due to tougher comps but we expect earnings upside to drive shares higher. We expect the ECLIPSE trial and Japan to drive strong coronary growth in coming years." (7/14/2017)
- 2. According to Zacks Investment Research, "Cardiovascular Systems posted solid second quarter of fiscal 2017, with both earnings and sales ahead of the respective Zacks Consensus Estimate. We are also encouraged by the company’s improving operating expense scenario, driving year-over-year rise in the earnings figure. Per management, the company delivered improved results over the past four quarters, showing major progress in driving revenue growth, while moving toward positive cash flow and profitability. On the flip side, share price trend over the past one month that traded below the broader Medical Products Industry. The company operates in the competitive medical device industry. Additionally, the company expects to witness net loss in the next third quarter a rise in its general and administrative expenses with growth in its business. All these indicate that there is no near term respite from the continuing operating loss structure." (3/16/2017)
Who are some of Cardiovascular Systems' key competitors?
Some companies that are related to Cardiovascular Systems include Haemonetics Corporation (HAE), Inogen (INGN), Halyard Health (HYH), MiMedx Group (MDXG), CONMED Corporation (CNMD), K2M Group Holdings (KTWO), Asante Solutions (PUMP), OraSure Technologies (OSUR), Orthofix International N.V. (OFIX), Intersect ENT (XENT), AtriCure (ATRC), CryoLife (CRY), Meridian Bioscience (VIVO), Landauer (LDR), Invacare Corporation (IVC), Consort Medical plc (CSRT), Antares Pharma (ATRS) and Exactech (EXAC).
Who are Cardiovascular Systems' key executives?
Cardiovascular Systems' management team includes the folowing people:
- Scott R. Ward, Chairman of the Board, President, Chief Executive Officer
- Laurence L. Betterley, Chief Financial Officer
- Kevin J. Kenny, Chief Operating Officer
- Martha Goldberg Aronson, Independent Director
- Scott A. Bartos, Independent Director
- Brent G. Blackey, Independent Director
- Edward M. Brown, Independent Director
- William E. Cohn M.D., Independent Director
Who owns Cardiovascular Systems stock?
Cardiovascular Systems' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.16%), First Quadrant L P CA (0.13%), Meeder Asset Management Inc. (0.09%), Acadian Asset Management LLC (0.08%), Quotient Investors LLC (0.06%) and Fox Run Management L.L.C. (0.03%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Brent G Blackey, Camber Capital Management Llc, David Martin, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Paul A Koehn, Robert J Thatcher and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.
Who sold Cardiovascular Systems stock? Who is selling Cardiovascular Systems stock?
Cardiovascular Systems' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, First Quadrant L P CA and Bank of Montreal Can. Company insiders that have sold Cardiovascular Systems stock in the last year include Alexander Rosenstein, Camber Capital Management Llc, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley and Paul A Koehn. View Insider Buying and Selling for Cardiovascular Systems.
Who bought Cardiovascular Systems stock? Who is buying Cardiovascular Systems stock?
Cardiovascular Systems' stock was acquired by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C. and Winslow Evans & Crocker Inc.. Company insiders that have bought Cardiovascular Systems stock in the last two years include Brent G Blackey, Camber Capital Management Llc and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.
How do I buy Cardiovascular Systems stock?
Shares of Cardiovascular Systems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cardiovascular Systems' stock price today?
One share of Cardiovascular Systems stock can currently be purchased for approximately $32.72.
MarketBeat Community Rating for Cardiovascular Systems (NASDAQ CSII)MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cardiovascular Systems (NASDAQ:CSII) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 4 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 2.83) |
| Consensus Price Target: | $34.40 (5.13% upside) |
Analysts' Ratings History for Cardiovascular Systems (NASDAQ:CSII)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/14/2017 | Needham & Company LLC | Reiterated Rating | Buy | $32.00 -> $37.00 | High |  |
| 6/21/2017 | Bank of America Corporation | Downgrade | Neutral -> Underperform | | Low | |
| 1/30/2017 | Lake Street Capital | Initiated Coverage | Buy | $40.00 | N/A | |
| 11/15/2016 | Leerink Swann | Reiterated Rating | Outperform | $30.00 | N/A | |
| 10/27/2016 | Feltl & Co. | Upgrade | Buy -> Strong-Buy | $30.00 | N/A | |
| 10/7/2016 | JMP Securities | Initiated Coverage | Outperform | $35.00 | N/A | |
| 12/23/2015 | Northcoast Research | Initiated Coverage | Buy | $18.00 | N/A | |
| 10/8/2015 | William Blair | Reiterated Rating | Outperform | | N/A | |
| 10/8/2015 | Dougherty & Co | Lower Price Target | Buy | $50.00 -> $32.00 | N/A | |
| 10/8/2015 | Benchmark Co. | Lower Price Target | Buy | $49.00 -> $20.00 | N/A | |
(Data available from 7/25/2015 forward)
Earnings History for Cardiovascular Systems (NASDAQ:CSII)Earnings History by Quarter for Cardiovascular Systems (NASDAQ CSII)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/1/2017 | | ($0.05) | | | | | N/A | |
| 5/3/2017 | Q3 2017 | ($0.05) | ($0.05) | $51.13 million | $52.10 million | View | Listen | |
| 1/25/2017 | Q217 | ($0.06) | $0.03 | $49.72 million | $50.00 million | View | N/A | |
| 10/26/2016 | Q117 | ($0.18) | ($0.06) | $205.50 million | $49.80 million | View | Listen | |
| 8/3/2016 | Q416 | ($0.20) | ($0.15) | $46.01 million | $48.50 million | View | N/A | |
| 5/4/2016 | Q316 | ($0.54) | ($0.31) | $42.13 million | $44.50 million | View | N/A | |
| 1/21/2016 | Q216 | ($0.50) | ($0.47) | $44.82 million | $41.40 million | View | Listen | |
| 11/4/2015 | Q116 | ($0.42) | ($0.41) | $43.90 million | $43.90 million | View | N/A | |
| 8/5/2015 | Q415 | ($0.30) | ($0.27) | $50.10 million | $48.50 million | View | N/A | |
| 4/29/2015 | Q315 | ($0.33) | ($0.34) | $46.84 million | $47.00 million | View | Listen | |
| 1/28/2015 | Q215 | ($0.34) | ($0.17) | $43.97 million | $44.70 million | View | Listen | |
| 10/29/2014 | Q115 | ($0.33) | ($0.26) | $40.24 million | $41.40 million | View | Listen | |
| 8/6/2014 | Q214 | ($0.28) | ($0.31) | $37.21 million | $39.56 million | View | Listen | |
| 4/30/2014 | Q114 | ($0.32) | ($0.32) | $34.15 million | $34.90 million | View | Listen | |
| 1/29/2014 | Q2 | ($0.34) | ($0.32) | $30.62 million | $32.30 million | View | Listen | |
| 8/7/2013 | Q4 2013 | ($0.30) | ($0.28) | $27.18 million | $28.80 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cardiovascular Systems (NASDAQ:CSII)2017 EPS Consensus Estimate: ($0.45)
2018 EPS Consensus Estimate: $0.14
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | ($0.44) | ($0.14) | ($0.26) |
| Q2 2017 | 4 | ($0.26) | ($0.05) | ($0.11) |
| Q3 2017 | 4 | ($0.05) | ($0.02) | ($0.04) |
| Q4 2017 | 4 | ($0.06) | ($0.02) | ($0.04) |
| Q1 2018 | 4 | ($0.01) | $0.02 | $0.00 |
| Q2 2018 | 4 | $0.01 | $0.03 | $0.02 |
| Q3 2018 | 3 | $0.03 | $0.05 | $0.04 |
| Q4 2018 | 4 | $0.03 | $0.09 | $0.07 |
(Data provided by Zacks Investment Research)
Dividend History for Cardiovascular Systems (NASDAQ:CSII)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cardiovascular Systems (NASDAQ:CSII)Insider Ownership Percentage: 3.60%
Institutional Ownership Percentage: 75.83%
Insider Trades by Quarter for Cardiovascular Systems (NASDAQ:CSII)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/17/2017 | Alexander Rosenstein | General Counsel | Sell | 219 | $32.30 | $7,073.70 | |
| 11/18/2016 | Alexander Rosenstein | General Counsel | Sell | 529 | $26.80 | $14,177.20 | |
| 11/18/2016 | Edward M Brown | Director | Sell | 10,000 | $26.78 | $267,800.00 | |
| 11/18/2016 | Laura Gillund | Insider | Sell | 1,268 | $26.79 | $33,969.72 | |
| 11/15/2016 | Edward M Brown | Director | Sell | 10,000 | $24.95 | $249,500.00 | |
| 10/10/2016 | Paul A Koehn | SVP | Sell | 30,910 | $25.07 | $774,913.70 | |
| 9/20/2016 | Camber Capital Management Llc | Major Shareholder | Sell | 1,100,000 | $23.26 | $25,586,000.00 | |
| 9/7/2016 | Paul A Koehn | SVP | Sell | 5,969 | $25.02 | $149,344.38 | |
| 8/22/2016 | Alexander Rosenstein | General Counsel | Sell | 234 | $23.82 | $5,573.88 | |
| 8/22/2016 | Kevin J Kenny | COO | Sell | 3,166 | $23.95 | $75,825.70 | |
| 8/22/2016 | Laura Gillund | Insider | Sell | 1,395 | $23.93 | $33,382.35 | |
| 8/22/2016 | Laurence L Betterley | CFO | Sell | 3,568 | $23.96 | $85,489.28 | |
| 8/22/2016 | Paul A Koehn | SVP | Sell | 2,527 | $23.92 | $60,445.84 | |
| 8/17/2016 | Paul A Koehn | SVP | Sell | 4,000 | $22.17 | $88,680.00 | |
| 2/26/2016 | Paul A Koehn | SVP | Sell | 956 | $38.79 | $37,083.24 | |
| 2/23/2016 | Camber Capital Management Llc | Major Shareholder | Buy | 250,000 | $7.55 | $1,887,500.00 | |
| 1/25/2016 | Scott R Ward | CEO | Buy | 2,700 | $9.30 | $25,110.00 | |
| 10/2/2015 | Robert J. Thatcher | insider | Sell | 64,700 | $16.31 | $1,055,257.00 | |
| 9/2/2015 | David Martin | CEO | Sell | 19,646 | $23.81 | $467,771.26 | |
| 9/1/2015 | Kevin J Kenny | COO | Sell | 5,289 | $23.85 | $126,142.65 | |
| 9/1/2015 | Laurence L Betterley | CFO | Sell | 9,597 | $23.96 | $229,944.12 | |
| 9/1/2015 | Paul A Koehn | SVP | Sell | 4,946 | $23.86 | $118,011.56 | |
| 9/1/2015 | Robert J Thatcher | Insider | Sell | 5,282 | $23.85 | $125,975.70 | |
| 8/18/2015 | David Martin | CEO | Sell | 17,688 | $23.99 | $424,335.12 | |
| 8/18/2015 | Kevin J. Kenny | COO | Sell | 3,913 | $24.00 | $93,912.00 | |
| 8/18/2015 | Laurence L Betterley | CFO | Sell | 8,476 | $24.00 | $203,424.00 | |
| 8/18/2015 | Paul A. Koehn | SVP | Sell | 4,402 | $23.99 | $105,603.98 | |
| 8/18/2015 | Robert J. Thatcher | insider | Sell | 2,960 | $23.99 | $71,010.40 | |
| 8/12/2015 | Brent G Blackey | Director | Buy | 2,500 | $22.74 | $56,850.00 | |
| 5/28/2015 | Paul A Koehn | SVP | Sell | 4,389 | $27.86 | $122,277.54 | |
| 5/1/2015 | Brent G Blackey | Director | Buy | 2,500 | $29.38 | $73,450.00 | |
| 2/10/2015 | David Martin | CEO | Sell | 7,500 | $35.85 | $268,875.00 | |
| 2/5/2015 | David Martin | CEO | Sell | 4,500 | $34.96 | $157,320.00 | |
| 1/29/2015 | Kevin J Kenny | VP | Sell | 4,212 | $35.00 | $147,420.00 | |
| 9/3/2014 | David Martin | CEO | Sell | 10,248 | $28.85 | $295,654.80 | |
| 9/3/2014 | Kevin J Kenny | VP | Sell | 3,528 | $28.85 | $101,782.80 | |
| 9/3/2014 | Laurence L Betterley | CFO | Sell | 4,674 | $28.82 | $134,704.68 | |
| 9/3/2014 | Paul A Koehn | SVP | Sell | 2,612 | $28.85 | $75,356.20 | |
| 9/3/2014 | Robert J Thatcher | Insider | Sell | 2,791 | $28.85 | $80,520.35 | |
| 8/28/2014 | Paul A Koehn | SVP | Sell | 1,315 | $28.82 | $37,898.30 | |
| 8/22/2014 | David Martin | CEO | Sell | 13,957 | $29.03 | $405,171.71 | |
| 8/22/2014 | Kevin J Kenny | VP | Sell | 2,914 | $29.09 | $84,768.26 | |
| 8/22/2014 | Laurence L Betterley | CFO | Sell | 6,578 | $29.02 | $190,893.56 | |
| 8/22/2014 | Paul A Koehn | SVP | Sell | 2,755 | $29.06 | $80,060.30 | |
| 8/22/2014 | Robert J Thatcher | Insider | Sell | 3,225 | $29.06 | $93,718.50 | |
| 8/19/2014 | David Martin | CEO | Sell | 11,754 | $29.28 | $344,157.12 | |
| 8/19/2014 | Kevin J Kenny | VP | Sell | 2,117 | $29.28 | $61,985.76 | |
| 8/19/2014 | Laurence L Betterley | CFO | Sell | 5,725 | $29.28 | $167,628.00 | |
| 8/19/2014 | Paul A Koehn | SVP | Sell | 2,168 | $29.28 | $63,479.04 | |
| 8/19/2014 | Robert J Thatcher | Insider | Sell | 2,537 | $29.28 | $74,283.36 | |
| 7/16/2014 | David Martin | CEO | Sell | 10,703 | $28.83 | $308,567.49 | |
| 7/16/2014 | Kevin J Kenny | VP | Sell | 3,007 | $28.83 | $86,691.81 | |
| 7/16/2014 | Laurence L Betterley | CFO | Sell | 3,984 | $28.83 | $114,858.72 | |
| 7/16/2014 | Paul A Koehn | SVP | Sell | 2,716 | $28.83 | $78,302.28 | |
| 7/16/2014 | Robert J Thatcher | Insider | Sell | 2,939 | $28.83 | $84,731.37 | |
| 4/25/2014 | Kevin Kenny | VP | Sell | 15,484 | $28.79 | $445,784.36 | |
| 2/24/2014 | David Martin | CEO | Sell | 29,200 | $37.31 | $1,089,452.00 | |
| 2/20/2014 | Kevin Kenny | VP | Sell | 6,779 | $36.02 | $244,179.58 | |
| 1/30/2014 | David Martin | CEO | Sell | 50,000 | $35.12 | $1,756,000.00 | |
| 1/30/2014 | Robert Thatcher | VP | Sell | 35,139 | $35.06 | $1,231,973.34 | |
| 11/22/2013 | Robert Thatcher | VP | Sell | 22,384 | $32.82 | $734,642.88 | |
| 10/31/2013 | James E Flaherty | Insider | Sell | 34,819 | $30.35 | $1,056,756.65 | |
| 10/23/2013 | David Martin | CEO | Sell | 154,080 | $27.73 | $4,272,638.40 | |
| 10/23/2013 | James E Flaherty | Insider | Sell | 36,682 | $26.85 | $984,911.70 | |
| 10/23/2013 | Robert J Thatcher | VP | Sell | 23,426 | $28.19 | $660,378.94 | |
| 10/22/2013 | Kevin J Kenny | VP | Sell | 5,608 | $27.31 | $153,154.48 | |
| 10/16/2013 | Kevin J Kenny | VP | Sell | 4,182 | $22.95 | $95,976.90 | |
| 10/14/2013 | David Martin | CEO | Sell | 21,170 | $22.00 | $465,740.00 | |
| 9/20/2013 | David Martin | CEO | Sell | 6,702 | $20.24 | $135,648.48 | |
| 9/20/2013 | James Flaherty | Insider | Sell | 2,066 | $20.28 | $41,898.48 | |
| 9/20/2013 | Robert Thatcher | VP | Sell | 1,274 | $20.28 | $25,836.72 | |
| 9/19/2013 | Laurence Betterley | CFO | Sell | 2,694 | $20.32 | $54,742.08 | |
| 9/19/2013 | Paul Koehn | SVP | Sell | 1,094 | $20.32 | $22,230.08 | |
| 9/18/2013 | David Martin | CEO | Sell | 8,030 | $20.94 | $168,148.20 | |
| 9/18/2013 | James Flaherty | Insider | Sell | 2,970 | $20.94 | $62,191.80 | |
| 9/18/2013 | Laurence Betterley | CFO | Sell | 4,324 | $20.93 | $90,501.32 | |
| 9/18/2013 | Paul Koehn | SVP | Sell | 1,732 | $20.93 | $36,250.76 | |
| 9/18/2013 | Robert Thatcher | VP | Sell | 1,731 | $20.94 | $36,247.14 | |
| 9/10/2013 | John Friedman | Director | Sell | 48,273 | $20.73 | $1,000,699.29 | |
| 8/30/2013 | David Martin | CEO | Sell | 21,552 | $20.64 | $444,833.28 | |
| 8/30/2013 | James Flaherty | Insider | Sell | 7,165 | $20.64 | $147,885.60 | |
| 8/30/2013 | Kevin Kenny | VP | Sell | 1,899 | $20.64 | $39,195.36 | |
| 8/30/2013 | Laurence Betterley | CFO | Sell | 8,692 | $20.64 | $179,402.88 | |
| 8/27/2013 | David Martin | CEO | Sell | 27,229 | $21.07 | $573,715.03 | |
| 8/27/2013 | James Flaherty | Insider | Sell | 9,051 | $21.07 | $190,704.57 | |
| 8/27/2013 | Kevin Kenny | VP | Sell | 2,396 | $21.07 | $50,483.72 | |
| 8/27/2013 | Laurence Betterley | CFO | Sell | 10,982 | $21.07 | $231,390.74 | |
| 8/16/2013 | James Flaherty | Insider | Sell | 1,255 | $20.51 | $25,740.05 | |
| 8/16/2013 | Laurence Betterley | CFO | Sell | 1,568 | $20.51 | $32,159.68 | |
| 8/14/2013 | James Flaherty | Insider | Sell | 4,902 | $21.31 | $104,461.62 | |
| 8/13/2013 | Kevin Kenny | VP | Sell | 2,529 | $21.20 | $53,614.80 | |
| 8/8/2013 | James Flaherty | Insider | Sell | 19,649 | $22.27 | $437,583.23 | |
| 7/30/2013 | David Martin | CEO | Sell | 11,094 | $19.69 | $218,440.86 | |
| 7/30/2013 | Laurence L Betterley | CFO | Sell | 6,579 | $19.72 | $129,737.88 | |
| 7/30/2013 | Robert J Thatcher | VP | Sell | 3,112 | $19.86 | $61,804.32 | |
| 6/3/2013 | James E Flaherty | Insider | Sell | 10,000 | $21.00 | $210,000.00 | |
| 5/31/2013 | Paul A Koehn | VP | Sell | 2,472 | $20.00 | $49,440.00 | |
| 5/28/2013 | Kevin J Kenny | VP | Sell | 4,182 | $19.95 | $83,430.90 | |
| 5/20/2013 | Glen D Nelson | Director | Buy | 10,250 | $18.47 | $189,317.50 | |
| 5/16/2013 | Glen D Nelson | Director | Buy | 4,753 | $18.93 | $89,974.29 | |
| 5/13/2013 | Glen D Nelson | Director | Buy | 18,393 | $18.11 | $333,097.23 | |
| 11/13/2012 | Glen D Nelson | Director | Buy | 33,000 | $11.96 | $394,680.00 | |
| 8/23/2012 | David Martin | CEO | Sell | 10,510 | $9.07 | $95,325.70 | |
| 8/23/2012 | James E Flaherty | Insider | Sell | 4,018 | $9.07 | $36,443.26 | |
| 8/23/2012 | Laurence L Betterley | CFO | Sell | 4,770 | $9.07 | $43,263.90 | |
| 8/23/2012 | Paul A Koehn | VP | Sell | 2,496 | $9.07 | $22,638.72 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cardiovascular Systems (NASDAQ:CSII)
Latest Headlines for Cardiovascular Systems (NASDAQ:CSII)
| Source: |
|
| Date | Headline |
|---|
 | Cardiovascular Systems, Inc. (NASDAQ:CSII) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - July 25 at 7:18 AM |
| BidaskClub Lowers Cardiovascular Systems, Inc. (CSII) to Hold
www.americanbankingnews.com - July 16 at 3:28 PM |
| Needham & Company LLC Reaffirms "Buy" Rating for Cardiovascular Systems, Inc. (CSII)
www.americanbankingnews.com - July 14 at 9:38 AM |
| Cardiovascular Systems, Inc. (CSII) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 14 at 9:08 AM |
 | Cardiovascular Systems to Webcast Fiscal 2017 Fourth-Quarter Earnings Conference Call Wednesday, August 2 - Business Wire (press release)
www.businesswire.com - July 12 at 11:22 PM |
 | Cardiovascular Systems to Webcast Fiscal 2017 Fourth-Quarter Earnings Conference Call Wednesday, August 2
finance.yahoo.com - July 12 at 6:19 PM |
| Cardiovascular Systems, Inc. (NASDAQ:CSII) Expected to Announce Quarterly Sales of $52.04 Million
www.americanbankingnews.com - July 6 at 9:16 AM |
| Zacks: Brokerages Expect Cardiovascular Systems, Inc. (CSII) Will Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - July 5 at 12:22 AM |
| Cardiovascular Systems (CSII) in Focus: Stock Moves 8.4% Higher
finance.yahoo.com - June 29 at 6:49 PM |
| Cardiovascular Systems, Inc. breached its 50 day moving average in a Bearish Manner : CSII-US : June 28, 2017
finance.yahoo.com - June 28 at 5:27 PM |
| ETFs with exposure to Cardiovascular Systems, Inc. : June 26, 2017
finance.yahoo.com - June 26 at 5:19 PM |
 | Cardiovascular Systems (CSII) Presents At JMP Securities Life Sciences Conference - Slideshow
seekingalpha.com - June 22 at 9:53 PM |
| Cardiovascular Systems, Inc. (CSII) Stock Rating Lowered by Bank of America Corporation
www.americanbankingnews.com - June 21 at 11:20 AM |
| Cardiovascular Systems, Inc. (CSII) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 19 at 8:00 AM |
| ETFs with exposure to Cardiovascular Systems, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 5:17 PM |
| Cardiovascular Systems, Inc. :CSII-US: Earnings Analysis: Q3, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 5:28 PM |
| Cardiovascular Systems to Present at the JMP Securities Life Sciences Conference
finance.yahoo.com - June 14 at 5:28 PM |
| Cardiovascular Systems Inc (CSII) Upgraded at BidaskClub
www.americanbankingnews.com - June 10 at 9:20 AM |
| $52.04 Million in Sales Expected for Cardiovascular Systems Inc (CSII) This Quarter
www.americanbankingnews.com - June 10 at 7:34 AM |
 | Adherium Appoints New CEO to Drive Global Growth
feeds.benzinga.com - June 9 at 10:58 AM |
| Zacks: Brokerages Expect Cardiovascular Systems Inc (CSII) Will Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - June 9 at 12:08 AM |
 | Commit To Purchase Cardiovascular Systems At $25, Earn 9.2% Annualized Using Options
www.nasdaq.com - June 8 at 10:33 PM |
| Cardiovascular Systems (CSII) Up 2.3% Since Earnings Report: Can It Continue?
finance.yahoo.com - June 6 at 4:46 PM |
| Cardiovascular Systems Inc (CSII) Short Interest Up 3.6% in May
www.americanbankingnews.com - May 29 at 12:38 PM |
| Cardiovascular Systems Inc (CSII) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 23 at 7:30 AM |
| -$0.05 Earnings Per Share Expected for Cardiovascular Systems Inc (CSII) This Quarter
www.americanbankingnews.com - May 12 at 8:28 PM |
| Cardiovascular Systems Inc (CSII) to Post FY2017 Earnings of ($0.12) Per Share, Northcoast Research Forecasts
www.americanbankingnews.com - May 8 at 10:24 AM |
| FY2017 EPS Estimates for Cardiovascular Systems Inc Cut by Analyst (CSII)
www.americanbankingnews.com - May 8 at 10:24 AM |
| Cardiovascular Systems Inc (CSII) Upgraded at TheStreet
www.americanbankingnews.com - May 8 at 12:28 AM |
| Leerink Swann Research Analysts Lift Earnings Estimates for Cardiovascular Systems Inc (CSII)
www.americanbankingnews.com - May 5 at 6:08 PM |
| Q1 2018 EPS Estimates for Cardiovascular Systems Inc Decreased by Analyst (CSII)
www.americanbankingnews.com - May 5 at 5:24 PM |
| Cardiovascular Systems Inc (CSII) Announces Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - May 4 at 11:10 PM |
| Investor Network: Cardiovascular Systems, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 4:41 PM |
| Cardiovascular Systems (CSII) Swings to Earnings in Q3
finance.yahoo.com - May 4 at 4:41 PM |
| FDA Approves Cardiovascular Systems’ Replacement Saline Infusion Pump
finance.yahoo.com - May 4 at 4:41 PM |
| Cardiovascular Systems' (CSII) CEO Scott Ward on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 6:59 AM |
| Edited Transcript of CSII earnings conference call or presentation 3-May-17 8:45pm GMT
finance.yahoo.com - May 4 at 6:59 AM |
| Cardiovascular Systems Inc (CSII) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 4 at 1:33 AM |
| Cardiovascular Systems Inc (CSII) Issues Q4 Earnings Guidance
www.americanbankingnews.com - May 4 at 1:13 AM |
| Cardiovascular Systems (CSII) Receives Media Impact Rating of 0.30
www.americanbankingnews.com - May 4 at 1:09 AM |
| Cardiovascular Systems Inc (CSII) Releases Q4 Earnings Guidance
www.americanbankingnews.com - May 3 at 11:04 PM |
 | Cardiovascular Systems reports 3Q loss
marketbeat.com - May 3 at 6:05 PM |
| Cardiovascular Systems, Inc. Reports Fiscal 2017 Third-Quarter Financial Results
finance.yahoo.com - May 3 at 4:29 PM |
| Somewhat Critical Media Coverage Extremely Likely to Affect Cardiovascular Systems (CSII) Share Price
www.americanbankingnews.com - April 30 at 11:39 AM |
| Cardiovascular Systems (CSII) Earning Somewhat Critical Press Coverage, Report Finds
www.americanbankingnews.com - April 27 at 5:44 PM |
 | Jury verdict to cost Cardiovascular Systems $25 million
www.bizjournals.com - April 27 at 2:09 AM |
| Cardiovascular Systems Inc (CSII) Receives Buy Rating from Needham & Company LLC
www.americanbankingnews.com - April 24 at 1:13 PM |
| Cardiovascular Systems (CSII) Given Daily News Impact Rating of 0.56
www.americanbankingnews.com - April 24 at 1:05 PM |
| Cardiovascular Systems Inc (CSII) Expected to Post Earnings of -$0.04 Per Share
www.americanbankingnews.com - April 24 at 12:06 PM |
| Somewhat Favorable Press Coverage Unlikely to Affect Cardiovascular Systems (CSII) Share Price
www.americanbankingnews.com - April 20 at 8:59 PM |
Cardiovascular Systems (CSII) Chart for Tuesday, July, 25, 2017
